PartitionBio

Executive Summary

PartitionBio is a UK-based biotech company founded in 2022 that is developing BubbleFect, a novel non-viral drug delivery platform based on engineered biomolecular condensates. The platform enables safe, efficient, and room-temperature-stable intracellular delivery of diverse biologics, including nucleic acids, proteins, and CRISPR components. By addressing key limitations of traditional delivery methods such as viral vectors and lipid nanoparticles—including high cost, safety concerns, and scalability challenges—BubbleFect has the potential to unlock new therapeutic modalities and expand the reach of gene editing and protein therapeutics. The company is currently in the pre-clinical stage, focusing on in vitro and in vivo validation of its delivery technology. Given its innovative approach and the growing demand for next-generation delivery systems, PartitionBio is well-positioned to attract strategic partnerships and investment. However, as an early-stage private company, it faces significant technical and regulatory hurdles before reaching clinical development.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round75% success
• Q4 2026In Vivo Proof-of-Concept Data Publication65% success
• Q1 2027Pharmaceutical Partnership or Licensing Deal40% success